Blow the Launch -- Doom the Product
Executive Summary
A new IMS survey shows that payors are now virtually the most important determinant of marketplace success -- far more important, in most markets, including the US, than sales representatives, who are less influential than they have ever been. Moreover, marketers who can't create a strong market penetration within six months of launch, will almost certainly fail - no matter what they do - to be able to improve the sales curve.
You may also be interested in...
Sales of Acorda's Ampyra Off To Strong Start
Because of a host of variables, estimating a peak sales figure based on actual demand has been tricky for analysts, but payers are covering the drug and patients are demanding it.
Rising Payor Influence Means Successful Drug Launches are Rarer
Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.
Rising Payor Influence Means Successful Drug Launches are Rarer
Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.